International Diabetes Federation. IDF Diabetes Atlas. 11th Edition 2025. diabetesatlas.org. ISBN: 978-2-930229-96-6.

Lorenzatti A, Toth PP. New perspectives on atherogenic dyslipidaemia and cardiovascular disease. Eur Cardiol Rev 2020;15:e04. DOI: https://doi.org/10.15420/ecr.2019.06.

Soewondo P, Soegondo S, Suastika K, Pranoto A, Soeatmadji DW, Tjokroprawiro A. The DiabCare Asia 2008 study – Outcomes on control and complications of type 2 diabetic patients in Indonesia. Med J Indones. 2010;19:235-44. https://doi.org/10.13181/mji.v19i4.412.

Suastika K, Semadi IMS, Dwipayana IMP, Saraswati MR, Gotera W, Budhiarta AAG, Matsumoto K, Kajiwara N, Taniguchi T. Dyslipidemia in diabetes: a population-based study in Bali. Internat J General Med 2019:12;313–21. http://doi.org/10.2147/IJGM.S215548.

Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25:771-82. http://doi.org/10.5551/jat.RV17023.

Tomlinson B, Chan P, Lam CWK. Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. Expert Rev Endocrinol Metab. 2020. DOI: 10.1080/17446651.2020.1750949.

Giraldo-Gonzalez GC, Roman-Gonzalez A, Cañas F, Garcia A. Molecular mechanisms of type 2 diabetes-related heart disease and therapeutic insights. Int. J. Mol. Sci. 2025;26:4548. https://doi.org/ 10.3390/ijms26104548.

Kazibwe R, Jehopio J. Schaich CL, Rikhi R, Mirzai S, Chevli PA, Namutebi JH, Chebrolu S, O’Connor S, Yeboah J, Shapiro MD. Atherogenic dyslipidemia and incident cardiovascular events in high-risk hypertension. Progress Cardiovac 2025. https://doi.org/10.1016/j.pcad.2025.05.006.

Nakashima R, Ikeda S, Shinohara K, Matsumoto S, Yoshida D, Ono Y, Nakashima H, Miyamoto R, Matsushima S, Kishimoto J, Itoh H, Komuro I, Tsutsui H, Abe K. Triglyceride/high density lipoprotein cholesterol index and future cardiovascular events in diabetic patients without known cardiovascular disease. Scientific Reports. 2025; 15:9217. https://doi.org/10.1038/s41598-025-92933-6.

Zhang Y-Y, Yang X-Y, and Wan Q. Association between atherogenic

Index of plasma and type 2 diabetic complications: a cross-sectional study. Front Endocrinol. 2025;16:1537303. Doi: 10.3389/fendo.2025.1537303.

Zhang Y, Chen G, and Jing Y. Correlation between the atherogenic index of plasma and risk of diabetic retinopathy. Front Med. 2025;12:1565414. Doi: 10.3389/fmed.2025.1565414.

Gaita L, Timar B, Timar R, Fras Z, Gaita D, Banach M. Lipid disorders management strategies (2024) in prediabetic and diabetic patients. Pharmaceuticals. 2024;17:219. https://doi.org/10.3390/ph17020219.

American Diabetes Association. Cardiovascular disease and risk management: Standards of care in diabetes—2025. Diabetes Care 2025;48 (Suppl 1): S207–S238. https://doi.org/10.2337/dc25-S010.

Patel SB, Wyne KL, Alfreen S, Belalcazar LM, Bird MD, Coles S, Marrs JC, Peng CCH, Pulipati VP, Sultan S, Zilbermint M. American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults with Dyslipidemia. Endocrine Pract 2025; 31: 236-262. http://doi.org/10.1016/j.eprac.2024.09.016.